Halo-Bio RNAi Therapeutics, Inc.
Welcome to Halo-Bio RNAi Therapeutics Inc., a company utilizing the novel Asymmetric RNAi Platform to develop effective therapeutics which suppress disease-causing genes, outsmart virus, and remove off-target effects in gene silencing. Unlike any other company, Halo-Bio offers a new class of RNAi based technologies to fight bacterial disease.
Novel RNAi Therapeutics.
Unlike other RNAi technologies, Asymmetric RNAi is not based on dsRNA. This enables Halo-Bio to exclusively develop therapeutics that function in either Eukaryotic or even Prokaryotic cells, avoid mammalian immune responses, and anticipate the freedom to practice.
Halo-Bio Advantage
The unique features of the Asymmetric RNAi Platform allow our researchers to apply this unique approach to some of the toughest diseases on the planet. Diseases that might have previously been hard to treat like HIV, Cancer, Diabetes, Cholera, Influenza, etc.., are now treatable due to the advantages of Asymmetric RNAi Platform.
Partners and Collaborators
Halo-Bio is forming relationships with industry-leading researchers in fields relevant to our therapeutic targets.
Licensing
Commercial partners involved with Halo-Bio have access to rights associated therapeutics developed in the relationship.
A perfect family of molecules for gene modulation in both Eukaryotes and Prokaryotes.
endoGUIDE RNA
Fast, Silent, Specific. The endoGUIDE RNA recruits ubiquitous RNases for specific and rapid cleavage of any coding or non-coding target gene.
Asymmetric shRNA Precursors
(A-shRNA)
A novel RNA precursor for stable RNAi which involves both Dicer pre-processing and RISC active complexes. The advantage is that this novel precursor lacks the sense-strand based off-target found in traditional shRNA and can be produced in more cell stages.
Intellectual Property and Licensing.
Halo Bio owns national and international pending patents.
endoGUIDE RNA
(PATENT PENDING)The endoGUIDE RNA provides a new mechanism for gene silencing in bacteria and humans against coding or non-coding genes.
Asymmetric shRNA/siRNA Precursors
(PATENT PENDING)A-shRNA replaces shRNA with a novel RNA precursor that is more specific and pathway independent.
Multivalent RNA
(PATENT PENDING)Multivalent RNA is the first single-molecule for multi-site RNAi.
For more information regarding licensing or collaborations, please contact us directly.